Corbus Pharmaceuticals
CRBP
83 hedge funds and large institutions have $152M invested in Corbus Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 31 increasing their positions, 21 reducing their positions, and 6 closing their positions.
117% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 6
48% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 21
8% more funds holding
Funds holding: 77 → 83 (+6)
0.23% more ownership
Funds ownership: 1.28% → 1.51% (+0.23%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
8% less capital invested
Capital invested by funds: $166M → $152M (-$14M)
66% less call options, than puts
Call options by funds: $1.06M | Put options by funds: $3.15M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EMG
ETF Managers Group
Summit,
New Jersey
|
+$26.3M |
| 2 |
D.E. Shaw & Co
New York
|
+$3.56M |
| 3 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$1.03M |
| 4 |
IA
IFP Advisors
Tampa,
Florida
|
+$681K |
| 5 |
Millennium Management
New York
|
+$666K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$5.4M |
| 2 |
SC
Sculptor Capital
New York
|
-$2.27M |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$838K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$598K |
| 5 |
BlackRock
New York
|
-$534K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SWM
76
SeaCrest Wealth Management
Purchase,
New York
| $1K | – | – | – |
|
|
TWA
77
TCI Wealth Advisors
Tucson,
Arizona
| $1K | – | – | – |
|
|
TC
78
Trust Company
Manhattan,
Kansas
| $1K | – | – | – |
|
79
BNP Paribas Financial Markets
Paris,
France
| $93 | -$9.58K | -48 | -98% |
|
|
SC
80
Sculptor Capital
New York
| – | -$2.27M | -10,027 | Closed |
|
|
TI
81
Trexquant Investment
Stamford,
Connecticut
| – | -$321K | -1,418 | Closed |
|
|
GCP
82
GSA Capital Partners
London,
United Kingdom
| – | -$129K | -570 | Closed |
|
|
KFA
83
Kelleher Financial Advisors
New York
| – | -$86K | -383 | Closed |
|
|
CS
84
Credit Suisse
Zurich,
Switzerland
| – | -$79K | -351 | Closed |
|
|
APP
85
Avantax Planning Partners
Dubuque,
Iowa
| – | -$1K | -4 | Closed |
|
|
DWM
86
Doyle Wealth Management
St. Petersburg,
Florida
| – | +$200 | +1 | New |
|
|
GTAM
87
Global Trust Asset Management
West Palm Beach,
Florida
| – | +$399 | +2 | New |
|
|
PRC
88
Pearl River Capital
Niles,
Michigan
| – | +$399 | +2 | New |
|
|
GT
89
Glenmede Trust
Philadelphia,
Pennsylvania
| – | +$998 | +5 | New |
|
CRBP Hedge Fund Activity: Q4 2018 in Review
83 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Corbus Pharmaceuticals (CRBP) for Q4 2018, worth a combined $152M — down 8.4% from $166M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new CRBP positions and 6 closed out — a net gain of 7 holders — while 31 added to existing stakes and 21 trimmed.
The largest buyer was ETF Managers Group, opening a new position worth an estimated $26.3M. The largest seller was Fidelity Investments, cutting an estimated $5.4M.
- 83 institutional investors held Corbus Pharmaceuticals (CRBP) as of Q4 2018, up from 77 in Q3 2018.
- Funds reported $152M of Corbus Pharmaceuticals stock for Q4 2018, down 8.4% quarter-over-quarter.
- 13 funds opened new Corbus Pharmaceuticals positions in Q4 2018 and 6 closed out, a net change of +7 holders.
- The largest Corbus Pharmaceuticals buyer in Q4 2018 was ETF Managers Group, an estimated $26.3M added.
- The largest Corbus Pharmaceuticals seller in Q4 2018 was Fidelity Investments, an estimated $5.4M sold.
Based on aggregated 13F filings for Q4 2018.